Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

Bilal Chughtai; Dean S. Elterman; Richard Lee; Alexis E. te; Steven A. Kaplan

doi:10.1177/1756287212457115

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

Bilal Chughtai, Dean S. Elterman, Richard Lee, Alexis E. te, Steven A. Kaplan

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs – α-adrenergic blockers and 5α-reductase inhibitors – are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.

Original language	English
Pages (from-to)	267-272
Number of pages	6
Journal	Therapeutic Advances in Urology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1177/1756287212457115
State	Published - Oct 2012
Externally published	Yes

Keywords

5α reductase inhibitor
CombAT trial
benign prostatic hyperplasia
combination therapy benign prostatic hyperplasia
dutasteride
fixed-dose benign prostatic hyperplasia
lower urinary tract symptoms
tamsulosin
α-adrenergic blocker

Access to Document

10.1177/1756287212457115

Cite this

@article{55f2078336df4dd7b1518865714eef7e,

title = "Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia",

abstract = "Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs – α-adrenergic blockers and 5α-reductase inhibitors – are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.",

keywords = "5α reductase inhibitor, CombAT trial, benign prostatic hyperplasia, combination therapy benign prostatic hyperplasia, dutasteride, fixed-dose benign prostatic hyperplasia, lower urinary tract symptoms, tamsulosin, α-adrenergic blocker",

author = "Bilal Chughtai and Elterman, {Dean S.} and Richard Lee and te, {Alexis E.} and Kaplan, {Steven A.}",

year = "2012",

month = oct,

doi = "10.1177/1756287212457115",

language = "English",

volume = "4",

pages = "267--272",

journal = "Therapeutic Advances in Urology",

issn = "1756-2872",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

AU - Chughtai, Bilal

AU - Elterman, Dean S.

AU - Lee, Richard

AU - te, Alexis E.

AU - Kaplan, Steven A.

PY - 2012/10

Y1 - 2012/10

N2 - Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs – α-adrenergic blockers and 5α-reductase inhibitors – are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.

AB - Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs – α-adrenergic blockers and 5α-reductase inhibitors – are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.

KW - 5α reductase inhibitor

KW - CombAT trial

KW - benign prostatic hyperplasia

KW - combination therapy benign prostatic hyperplasia

KW - dutasteride

KW - fixed-dose benign prostatic hyperplasia

KW - lower urinary tract symptoms

KW - tamsulosin

KW - α-adrenergic blocker

UR - http://www.scopus.com/inward/record.url?scp=84871912150&partnerID=8YFLogxK

U2 - 10.1177/1756287212457115

DO - 10.1177/1756287212457115

M3 - Review article

AN - SCOPUS:84871912150

SN - 1756-2872

VL - 4

SP - 267

EP - 272

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

IS - 5

ER -

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

Abstract

Keywords

Access to Document

Fingerprint

Cite this